{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=91",
    "query": {
      "condition": "Cancer",
      "page": 91
    },
    "page_size": 10
  },
  "pagination": {
    "page": 91,
    "page_size": 10,
    "total_count": 50388,
    "total_pages": 5039,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=92&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=90&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T01:12:38.404Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02203773",
      "title": "Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Myelogenous Leukemia",
        "Treatment Naive AML"
      ],
      "interventions": [
        {
          "name": "Posaconazole",
          "type": "DRUG"
        },
        {
          "name": "ABT-199",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 212,
      "start_date": "2014-10-06",
      "completion_date": "2022-06-16",
      "has_results": false,
      "last_update_posted_date": "2023-05-16",
      "last_synced_at": "2026-11-04T01:12:38.404Z",
      "location_count": 13,
      "location_summary": "Duarte, California • Sacramento, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02203773"
    },
    {
      "nct_id": "NCT01365169",
      "title": "Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Malignant Head and Neck Neoplasm",
        "Malignant Neoplasm",
        "Metastatic Malignant Neoplasm in the Neck",
        "Metastatic Malignant Neoplasm in the Uterine Cervix",
        "Pancreatic Adenocarcinoma",
        "Pancreatic Neuroendocrine Carcinoma",
        "Recurrent Colorectal Carcinoma",
        "Stage I Colorectal Cancer AJCC v6 and v7",
        "Stage I Hypopharyngeal Carcinoma AJCC v7",
        "Stage I Major Salivary Gland Cancer AJCC v7",
        "Stage I Nasopharyngeal Carcinoma AJCC v7",
        "Stage I Oral Cavity Cancer AJCC v6 and v7",
        "Stage I Oropharyngeal Carcinoma AJCC v6 and v7",
        "Stage II Colorectal Cancer AJCC v7",
        "Stage II Hypopharyngeal Carcinoma AJCC v6 and v7",
        "Stage II Major Salivary Gland Cancer AJCC v7",
        "Stage II Nasopharyngeal Carcinoma AJCC v7",
        "Stage II Oral Cavity Cancer AJCC v6 and v7",
        "Stage II Oropharyngeal Carcinoma AJCC v6 and v7",
        "Stage IIA Colorectal Cancer AJCC v7",
        "Stage IIB Colorectal Cancer AJCC v7",
        "Stage IIC Colorectal Cancer AJCC v7",
        "Stage III Colorectal Cancer AJCC v7",
        "Stage III Hypopharyngeal Carcinoma AJCC v7",
        "Stage III Laryngeal Cancer AJCC v6 and v7",
        "Stage III Major Salivary Gland Cancer AJCC v7",
        "Stage III Nasopharyngeal Carcinoma AJCC v7",
        "Stage III Oral Cavity Cancer AJCC v6 and v7",
        "Stage III Oropharyngeal Carcinoma AJCC v7",
        "Stage IIIA Colorectal Cancer AJCC v7",
        "Stage IIIB Colorectal Cancer AJCC v7",
        "Stage IIIC Colorectal Cancer AJCC v7",
        "Stage IV Colorectal Cancer AJCC v7",
        "Stage IVA Colorectal Cancer AJCC v7",
        "Stage IVA Hypopharyngeal Carcinoma AJCC v7",
        "Stage IVA Laryngeal Cancer AJCC v7",
        "Stage IVA Major Salivary Gland Cancer AJCC v7",
        "Stage IVA Nasopharyngeal Carcinoma AJCC v7",
        "Stage IVA Oral Cavity Cancer AJCC v6 and v7",
        "Stage IVA Oropharyngeal Carcinoma AJCC v7",
        "Stage IVB Colorectal Cancer AJCC v7",
        "Stage IVB Hypopharyngeal Carcinoma AJCC v7",
        "Stage IVB Laryngeal Cancer AJCC v7",
        "Stage IVB Major Salivary Gland Cancer AJCC v7",
        "Stage IVB Nasopharyngeal Carcinoma AJCC v7",
        "Stage IVB Oral Cavity Cancer AJCC v6 and v7",
        "Stage IVB Oropharyngeal Carcinoma AJCC v7",
        "Metastatic or Locally Unresectable Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Exercise Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Health Telemonitoring",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 590,
      "start_date": "2011-05-25",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-11-04T01:12:38.404Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01365169"
    },
    {
      "nct_id": "NCT04049669",
      "title": "Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Medulloblastoma",
        "Ependymoma",
        "Diffuse Intrinsic Pontine Glioma"
      ],
      "interventions": [
        {
          "name": "Indoximod",
          "type": "DRUG"
        },
        {
          "name": "Partial Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Full-dose Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Lomustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Theodore S. Johnson",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 130,
      "start_date": "2019-10-02",
      "completion_date": "2027-12-11",
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-04T01:12:38.404Z",
      "location_count": 5,
      "location_summary": "Augusta, Georgia • Druid Hills, Georgia • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Druid Hills",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04049669"
    },
    {
      "nct_id": "NCT02507583",
      "title": "Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Glioma",
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "IGF-1R/AS ODN; Surgery with tissue harvest and implantation 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "david andrews",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2015-09-01",
      "completion_date": "2020-08-17",
      "has_results": false,
      "last_update_posted_date": "2025-05-07",
      "last_synced_at": "2026-11-04T01:12:38.404Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02507583"
    },
    {
      "nct_id": "NCT03638141",
      "title": "CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Intermediate Stage of Hepatocellular Carcinoma",
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2019-10-02",
      "completion_date": "2024-08-20",
      "has_results": true,
      "last_update_posted_date": "2025-08-17",
      "last_synced_at": "2026-11-04T01:12:38.404Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03638141"
    },
    {
      "nct_id": "NCT01728805",
      "title": "Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cutaneous T-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "KW-0761",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kyowa Kirin, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 372,
      "start_date": "2012-11",
      "completion_date": "2021-02-17",
      "has_results": true,
      "last_update_posted_date": "2024-04-25",
      "last_synced_at": "2026-11-04T01:12:38.404Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01728805"
    },
    {
      "nct_id": "NCT03655756",
      "title": "pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Cutaneous Melanoma, Stage III",
        "Cutaneous Melanoma, Stage IV"
      ],
      "interventions": [
        {
          "name": "IFx-Hu2.0",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "TuHURA Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2018-11-05",
      "completion_date": "2020-11-30",
      "has_results": true,
      "last_update_posted_date": "2022-08-08",
      "last_synced_at": "2026-11-04T01:12:38.404Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03655756"
    },
    {
      "nct_id": "NCT00268229",
      "title": "Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "daunorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "imatinib mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2003-07",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2013-02-15",
      "last_synced_at": "2026-11-04T01:12:38.404Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00268229"
    },
    {
      "nct_id": "NCT01056029",
      "title": "Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "G-202",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GenSpera, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2010-01",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2015-12-10",
      "last_synced_at": "2026-11-04T01:12:38.404Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • San Antonio, Texas • Madison, Wisconsin",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01056029"
    },
    {
      "nct_id": "NCT03134131",
      "title": "Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Glioma"
      ],
      "interventions": [
        {
          "name": "ONC201",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2022-03-14",
      "last_synced_at": "2026-11-04T01:12:38.404Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03134131"
    }
  ]
}